Last reviewed · How we verify
NCT04718402
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma
Phase 1 trial testing Mitoxantrone Hydrochloride Liposome, intravenous injection in Advanced Gastric Carcinoma in 21 participants. Terminated before completion.
30 May 2022
Quick facts
| Lead sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 30 March 2021 |
| Primary completion | 30 May 2022 |
| Estimated completion | 30 May 2022 |
| Sites | 9 locations across China |
Drugs / interventions tested
- Mitoxantrone Hydrochloride Liposome, intravenous injection — full drug profile →
Conditions studied
- Advanced Gastric Carcinoma — all drugs for Advanced Gastric Carcinoma →
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Advanced Gastric Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with advanced gastric carcinoma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Nanoparticles in the clinic: An update post COVID-19 vaccines.
Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246 -
Targeting Mitochondrial Metabolism to Reverse Radioresistance: An Alternative to Glucose Metabolism.
Bian C, Zheng Z, Su J, Wang H, et al · · 2022 · cited 11× · PMID 36358574 · DOI 10.3390/antiox11112202
Verify or expand the search:
- PubMed search for NCT04718402
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Gastric Carcinoma
Currently open trials in the same condition.
- NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
- NCT06642857 — Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastr · recruiting
- NCT05969860 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · Phase 2 · recruiting
- NCT05620732 — Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T · NA · recruiting
- NCT05226169 — Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) · Phase 3 · recruiting
Other CSPC ZhongQi Pharmaceutical Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07532655 — A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants · Phase 1 · not yet recruiting
- NCT07412353 — A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 · Phase 1 · recruiting
- NCT07282509 — Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of · Phase 1, PHASE2 · not yet recruiting
- NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
- NCT07241936 — A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04718402 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Last refreshed: 7 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04718402.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing